Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zabalafin in mild to moderate atopic dermatitis
NCT06855745Phase 2Recruiting
- Sponsor
- Alphyn Biologics
- Start
- Mar 2025
- Primary completion
- Oct 2025
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zabalafin in atopic dermatitis (AD), skin infection (SSTI), sponsored by Alphyn Biologics. Started Mar 2025; status: recruiting.
02
Drugs
zabalafin
03
Conditions
atopic dermatitis (AD)skin infection (SSTI)
Beyond the preview
Go deeper on NCT06855745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855745.